Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study

Autor: Thierry André, Alfredo Falcone, Yaroslav Shparyk, Fedor Moiseenko, Eduardo Polo-Marques, Tibor Csöszi, Arinilda Campos-Bragagnoli, Gabor Liposits, Ewa Chmielowska, Paul Aubel, Lourdes Martín, Ronan Fougeray, Nadia Amellal, Mark P Saunders

Publikováno v: André, T, Falcone, A, Shparyk, Y, Moiseenko, F, Polo-Marques, E, Csöszi, T, Campos-Bragagnoli, A, Liposits, G, Chmielowska, E, Aubel, P, Martín, L, Fougeray, R, Amellal, N & Saunders, M P 2023, ' Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE) : a randomised, open-label phase 3 study ', The Lancet. Gastroenterology & hepatology, vol. 8, no. 2, pp. 133-144 . https://doi.org/10.1016/S2468-1253(22)00334-X

Background: Trifluridine–tipiracil plus bevacizumab has shown efficacy in previous phase 2 studies including patients with unresectable metastatic colorectal cancer. We aimed to investigate first-line trifluridine–tipiracil plus bevacizumab versu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cadad6db1d3357344ba4d26926f5a7a
https://pubmed.ncbi.nlm.nih.gov/36470291

Drugs and the FDA : Safety, Efficacy, and the Public's Trust

Autor: Mikkael A. Sekeres

How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutical evaluation of bevacizumab application in relapsed pterygium

Autor: Mayara Martins Abrahao, Leonardo Pinheiro Teixeira, Luana Miranda Campos, Mateus Martins Cortez Vilar, João Jorge Nassaralla Junior, Denise Borges de Andrade Mendanha

Publikováno v: Revista Brasileira de Oftalmologia v.76 n.5 2017
Revista Brasileira de Oftalmologia
Sociedade Brasileira de Oftalmologia (SBO)
instacron:SBO
Revista Brasileira de Oftalmologia, Vol 76, Iss 5, Pp 232-235

Objective: Therapeutic evaluation of Bevacizumab application in relapsed pterygium concerning visual acuity, keratometry, refraction, symptomatology. Methods: Group 1 (4 patients) received 0.1 ml of Bevacizumab (avastin), being evaluated posteriorly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31eebcaf9ec8a62164190cde1d87577d
https://doi.org/10.5935/0034-7280.20170048

Lipid corneal degeneration after trabeculectomy with mitomicin 0.02%

Autor: Stival, Larissa Rossana Souza, Chaves, Luis Fernando Oliveira Borges, Sauter, Karine, Beniz, Luiz Arthur Franco, Soares, Jordana Sandes Barbosa, Rodrigues, Francisco Wellington, Toledo, Marcia Cristina, Beniz, José

Publikováno v: Revista Brasileira de Oftalmologia, Volume: 75, Issue: 6, Pages: 470-472, Published: DEC 2016

One patient with a history of trabeculectomy with Mitomicin C 0.02%, but no history of systemic disorders, exhibited unilateral corneal lipid infiltrates, together with deep stromal vascularization. She was treated with a bevacizumab injection and pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______608::0eafba55419febbb7e84cf4f4850a7f5
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-72802016000600470&lng=en&tlng=en